retatrutide safety trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide—A Game Changer in Obesity

Hers and Hims now offer access to GLP-1 medications like semaglutide and tirzepatide to help with weight loss

NICE recommends it (Technology Appraisal TA875) for adults with a BMI of 35 kg/m or above with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in certain higher-risk groups, when used within a specialist Tier 3 or Tier 4 weight management service alongside a reduced-calorie diet and increased physical activity

Brain 136 , 30383050 (2013)

Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans

Strokes are mostly caused by arterial occlusion, which in turn leads to cerebral ischemia, brain damage, and then nerve damage and disability

The net effect of potential receptor activation in the context of other metabolic changes is unclear and requires further investigation